In recent years, immunotherapy with PD-1/PD-L1 inhibitors has gained prominence in the treatment of advanced squamous cell carcinoma, especially in cases where traditional systemic therapy has shown limited efficacy. This evidence concerns the gene CD274 and squamous cell carcinoma.